279 related articles for article (PubMed ID: 31932492)
1. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
Current K; Meyer C; Magyar CE; Mona CE; Almajano J; Slavik R; Stuparu AD; Cheng C; Dawson DW; Radu CG; Czernin J; Lueckerath K
Clin Cancer Res; 2020 Jun; 26(12):2946-2955. PubMed ID: 31932492
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Lückerath K; Wei L; Fendler WP; Evans-Axelsson S; Stuparu AD; Slavik R; Mona CE; Calais J; Rettig M; Reiter RE; Herrmann K; Radu CG; Czernin J; Eiber M
EJNMMI Res; 2018 Oct; 8(1):96. PubMed ID: 30374743
[TBL] [Abstract][Full Text] [Related]
3. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
[TBL] [Abstract][Full Text] [Related]
4. Establishing
Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K
J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332
[TBL] [Abstract][Full Text] [Related]
5. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
7. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
8. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
9. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
Stuparu AD; Capri JR; Meyer CAL; Le TM; Evans-Axelsson SL; Current K; Lennox M; Mona CE; Fendler WP; Calais J; Eiber M; Dahlbom M; Czernin J; Radu CG; Lückerath K; Slavik R
J Nucl Med; 2021 Jul; 62(7):989-995. PubMed ID: 33277393
[TBL] [Abstract][Full Text] [Related]
11. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeling of PSMA-617 with
Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
15. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
17. Radioligand Therapy With
Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
[No Abstract] [Full Text] [Related]
18. Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.
Inubushi M; Miura H; Kuji I; Ito K; Minamimoto R
Ann Nucl Med; 2020 Dec; 34(12):879-883. PubMed ID: 33175360
[TBL] [Abstract][Full Text] [Related]
19. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands.
Tschan VJ; Borgna F; Schibli R; Müller C
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):470-480. PubMed ID: 34402925
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of [
Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
